secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nurix Therapeutics, Inc. (NRIX)
CIK:        0001549595
Form:       8-K
Filed at:   2026-01-12T23:59:59+00:00
Accession:  0001549595-26-000003
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nurix outlines bexobrutideg pivotal CLL plan, 83% ORR, $664M cash at JPM
------------------------------------------------------------------------

- Phase 2 DAYBreak CLL-201 enrolled Oct 2025; confirmatory Phase 3 vs pirtobrutinib planned in 2026.
- 83% ORR and 22.1-month median PFS in r/r CLL with median 4 prior lines; 600 mg dose aligned with regulators.
- New tablet formulation for autoimmune; IND target 2026. Partnered IRAK4 (GS-6791, Phase 1) and STAT6 (IND-enabling).
- NX-1607 Phase 1a showed immune activation; confirmed partial response in MSS CRC across 82 patients.
- Pro forma cash $663.8M after $250M equity raise; added CCO and two new board members.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000003/0001549595-26-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1549595/000154959526000003/nrix-20260112.htm
  HTML page:      https://secwatch.observer/filing/0001549595-26-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer